← Evidence map

ArticleJournal of clinical pharmacology2026

FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease.

Poonam R Delvadia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. | OpenQuestion